Sevelamer hydrochloride is an orally active and phosphate binding agent used for research of hyperphosphatemia with chronic kidney disease. Sevelamer hydrochloride consists of polyallylamine that is crosslinked with epichlorohydrin^[1][2][3].

Sevelamer hydrochloride (15 mg/mL; pH=6 or 8) decreases serum levels of gut-derived uremic toxins (such as IAA) or limits the elevation of gut-derived uremic toxins (initial concentration=1 μg/mL or 10 μg/mL)^[2].

Sevelamer hydrochloride (1% mixed in diet; p.o.; once daily for 5 weeks) reduces Npt2b-deficient mice serum phosphate levels, but fails to reduce the level in uremic WT mice^[3].
Sevelamer hydrochloride leads to a significant decrease in osteoclast number in uremic WT mice with a trend toward further decrease in Npt2b^-/-mice^[3].
Sevelamer hydrochloride leads to a significant increase in Npt2b protein expression^[3].

186.08 (monomer)

Solid

(C₃H₇N.C₃H₅ClO)x.xHCl

152751-57-0

盐酸司维拉姆

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

H₂O :< 0.1 mg/mL(insoluble)

DMSO :< 1 mg/mL(insoluble or slightly soluble)